Results 191 to 200 of about 14,556 (244)

Microbial Cell-Free DNA Sequencing as a Novel Diagnostic for Culture-Negative Gemella haemolysans Endocarditis. [PDF]

JACC Case Rep
Koirala T, Sahoo P, Mahajan S, Pichilingue-Reto P, Jones R.   +4 more
europepmc   +1 more source

Harnessing plant‐based platform for low‐cost cellulosic sugar recovery from bioenergy crops

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The price of pure cellulase enzyme for the recovery of fermentable cellulosic sugars is one of the major challenges that limit the commercialization of second‐generation biofuels and bio‐based products. This work shows a means to greatly reduce the cost of cellulases. The abundant capacity of plants to synthesize and hyperaccumulate transgenic
Shraddha Maitra, Kristen Eilts, Raunak Bansal, Stephen P. Long, Vijay Singh   +4 more
wiley   +1 more source

Culture medium influences detectability of antimicrobial effects of autologous platelet concentrates against anaerobic periodontal pathogens. [PDF]

BMC Oral Health
Jansen EE, Braun A, Jansen P, Conrads G.
europepmc   +1 more source

A systematic scoping review of metrics utilized to measure antibiotic consumption in hospital settings

British Journal of Clinical Pharmacology, EarlyView.
Abstract Antimicrobial stewardship (AMS) programs were introduced to promote the judicious use of antimicrobials and to combat antimicrobial resistance. Quantifying antibiotic consumption is an important part of AMS initiatives to achieve these objectives.
Marjan Kandimahforoujaki, Kiplin A. Patanwala, Jan‐Willem C. Alffenaar, Asad E. Patanwala   +3 more
wiley   +1 more source

Epidemiological Insights into HACEK Bacteria: A Seven-year Retrospective Analysis at a Tertiary Care Center in Istanbul. [PDF]

Medeni Med J
Dundar T, Habip Z, Kocoglu ME, Ozekinci T.   +3 more
europepmc   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Odontogenic Brain Abscess in a Hereditary Haemorrhagic Telangiectasia (HHT) Patient: Case Report with a Comprehensive Literature Review. [PDF]

Trop Med Infect Dis
Westerström P, Bivand JM, Kommedal Ø, Ehrnström B, Andreassen JS, Afset JE.   +5 more
europepmc   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan, Cinzia Dello Russo, Jack Thompson, Dyfrig A. Hughes, Katherine Payne, Maria Tsakiroglou, Paul Ross, Rena Chauhan, Simon Jenkinson, Jessica Keen, Sophie Harding, Eleanor Lau, Michael Braun, Roshan Agarwal, Richard Adams, Elisabeth Rolf, Farah Al‐Sheikhli, Sarah Mitchell, Ruth Hammond, Rosie Roberts, Lorna Cairns, Shirley Heggarty, Janet Graham, Justin Mencel, Munir Pirmohamed   +24 more
wiley   +1 more source

Beyond the Petri Dish: The Performance of a Multiplex PCR-Based Pneumonia Panel in Hospitalized Patients With Lower Respiratory Tract Infection. [PDF]

Cureus
Naharia P, Sharma A, Bhatt P, Ravi AK, Joshi A, Karade S.   +5 more
europepmc   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source